{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:16:31Z","timestamp":1784798191680,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.msard.2022.103856","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T05:13:36Z","timestamp":1651814016000},"page":"103856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies"],"prefix":"10.1016","volume":"63","author":[{"given":"Asya I.","family":"Wallach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Schiebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Picone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103856_bib0001","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1016\/j.msard.2022.103856_bib0003","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2022.103856_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.3599","article-title":"Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab","author":"Brill","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2022.103856_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211038111","article-title":"Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab","volume":"14","author":"Capuano","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.msard.2022.103856_bib0007","article-title":"Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series","author":"Connolly","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.msard.2022.103856_bib0009","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaneurol.2021.3609","article-title":"Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis","volume":"78","author":"Disanto","year":"2021","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.103856_bib0006","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103856_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103251","article-title":"Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis","volume":"56","author":"Novak","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.msard.2022.103856_bib0010","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156978","article-title":"Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function","volume":"7","author":"Sabatino","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.msard.2022.103856_bib0005","doi-asserted-by":"crossref","unstructured":"Sormani M.P., Inglese M., Schiavetti I., et\u00a0al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. Oct 2021; 72: 103581. 10.1016\/j.ebiom.2021.103581.","DOI":"10.2139\/ssrn.3886420"},{"key":"10.1016\/j.msard.2022.103856_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:02:04Z","timestamp":1761901324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822003686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":11,"alternative-id":["S2211034822003686"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103856","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103856"}}